| Literature DB >> 21867549 |
Rebeca Santiso1, María Tamayo, Jaime Gosálvez, Germán Bou, María del Carmen Fernández, José Luis Fernández.
Abstract
BACKGROUND: Antibiotics which inhibit bacterial peptidoglycan biosynthesis are the most widely used in current clinical practice. Nevertheless, resistant strains increase dramatically, with serious economic impact and effects on public health, and are responsible for thousands of deaths each year. Critical clinical situations should benefit from a rapid procedure to evaluate the sensitivity or resistance to antibiotics that act at the cell wall. We have adapted a kit for rapid determination of bacterial DNA fragmentation, to assess cell wall integrity.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21867549 PMCID: PMC3179955 DOI: 10.1186/1471-2180-11-191
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Figure 1Images of susceptible (above: a, a', a''), intermediate (medium: b, b', b'') and resistant (below: c, c', c'') strains from . The strain is considered susceptible when its MIC is ≤ 8/4 and resistant when it is ≥ 32/16. a, b, c: control, without antibiotic. a', b', c': 8/4 μg/ml; a'', b'', c'': 32/16 μg/ml. Controls without antibiotic (a, b, c) show the bacteria unaffected by the lysis. After 8/4, only bacteria from the first strain, sensitive, appear lysed, showing the spread nucleoids (a'). After 32/16, first and second strains, sensitive and medium, respectively, show to be lysed (a'' and b''), whereas the third strain, resistant, appears not to be lysed (c''). Nevertheless, some isolated bacteria with damaged cell wall are visible. When the antibiotic is effective, besides the liberation of the nucleoids, it is observed a microgranular-fibrilar background of DNA fragments released by the bacteria.
Figure 2Nature of the microgranular-fibrilar extracellular background in an . Control culture without ampicillin does not show the microgranular-fibrilar extracellular background (a), whereas it is evident in cultures treated with ampicillin (b). Incubation of the microgels with specific buffers for DNase I (c) or proteinase K (e) does not affect the background. The specific proteinase K buffer lyses the bacteria. The background disappears after incubation with DNase I (d), but not after proteinase K treatment (f).
Figure 3Fluorescence . DAPI counterstaining (blue) evidences a faint background of aggregated material that encloses the bacteria that appear more strongly stained (a). The whole genome probe, revealed with Cy 3, red, labelled the nucleoids from bacteria and strongly hybridized with the aggregated background (b).
Figure 4Background DNA fragments in an . The strain was incubated with 0.76 μg/ml of the antibiotic. A high dilution of the culture before being enclosed in agarose microgel allows a more detailed visualization of the extracellular background, after SYBR Gold staining. It is evidenced that the background corresponds to DNA fragments in different levels of spreading, from a punctual appearance to an extended fiber.
Figure 5Categories of . From above to below: Unaffected, Weakly affected, Strongly affected, Strongly affected without recognizable cell body.
Figure 6Halo width of spreading of the nucleoids from the bacterial body from .
Figure 7Representative images of the effect of increasing doses of ampicillin in a susceptible strain of . a: control, 0 μg/ml; b: 2 μg/ml; c: MIC dose, 4 μg/ml; d: 8 μg/ml; e: 12 μg/ml.
Figure 8Proportions of the different categories of cell wall damage after increasing dose of ampicillin in susceptible .
Microorganisms evaluated for susceptibility-resistance to antibiotics that inhibit peptidoglycan synthesis
| Gram | Bacteria | Antibiotics- CLSI MIC Interpretative Standard (μg/mL) | CLSI Category | MIC (μg/ml) | Drug concentration at which the nucleoids were spread - and DNA fragments were released |
|---|---|---|---|---|---|
| Gram - | Imipenem: ≤ 4 - 8 - ≥16 (SI, R) | Susceptible | 2 | 4-4 | |
| Gram - | Imipenem: ≤ 4 - 8 - ≥16 (SI, R) | Intermediate | 8 | 16-16 | |
| Gram - | Imipenem: ≤ 4 - 8 - ≥16 (SI, R) | Resistant | > 16 | No nucleoids-No fragments | |
| Gram - | Imipenem: ≤ 4 - 8 - ≥16 (SI, R) | Resistant | > 16 | No nucleoids-No fragments | |
| Gram - | Ceftazidime: ≤ 8 - 16 - ≥32 (S, I, R) | Susceptible | 4 | 8-8 | |
| Gram - | Ceftazidime: ≤ 8 - 16 - ≥32 (S, I, R) | Intermediate | 12 | 32-32 | |
| Gram - | Ceftazidime: ≤ 8 - 16 - ≥32 (S, I, R) | Resistant | > 256 | No nucleoids-No fragments | |
| Gram - | Imipenem: ≤ 1 - 2 - ≥4 (S, I, R) | Susceptible | < 1 | 1-1 | |
| Gram - | Imipenem: ≤ 1 - 2 - ≥4 (S, I, R) | Susceptible | < 1 | 1-1 | |
| Gram - | Ceftazidime: ≤ 4 - 8 - ≥16 (S, I, R) | Susceptible | < 1 | 4-4 | |
| Gram - | Ceftazidime: ≤ 4 - 8 - ≥16 (S, I, R) | Susceptible | < 1 | 4-4 | |
| Gram - | Ampicillin: ≤ 8 - 16- ≥32 (S, I, R) | Susceptible | 2 | 8-8 | |
| Gram - | Ampicillin: ≤ 8 - 16- ≥32 (S, I, R) | Intermediate | 12 | 16-16 | |
| Gram - | Ampicillin: ≤ 8 - 16- ≥32 (S, I, R) | Resistant | 256 | No nucleoids-No fragments | |
| Gram - | Ceftazidime: ≤ 4 -8- ≥16 (S, I, R) | Susceptible | 0.25 | 4-4 | |
| Gram - | Ceftazidime: ≤ 4 -8- ≥16 (S, I, R) | Resistant | 32 | No nucleoids-No fragments | |
| Gram - | Imipenem: ≤ 1 - 2 - ≥4 (S, I, R) | Susceptible | < 1 | 1-1 | |
| Gram - | Ceftazidime: ≤ 4 - 8 - ≥16 (S, I, R) | Susceptible | < 1 | 4-4 | |
| Gram - | Imipenem: ≤ 1 - 2 - ≥4 (S, I, R) | Susceptible | < 1 | 1-1 | |
| Gram - | Imipenem: ≤ 1 - 2 - ≥4 (S, I, R) | Susceptible | < 1 | 1-1 | |
| Gram - | Imipenem: ≤ 1 - 2 - ≥4 (S, I, R) | Susceptible | < 1 | 1-1 | |
| Gram - | Ceftazidime: ≤ 4 - 8 - ≥16 (S, I, R) | Intermediate | 8 | 16-16 | |
| Gram - | Ceftazidime: ≤ 4 - 8 - ≥16 (S, I, R) | Resistant | > 16 | No nucleoids-No fragments | |
| Gram - | Ceftazidime: ≤ 4 - 8 - ≥16 (S, I, R) | Resistant | > 16 | No nucleoids-No fragments | |
| Gram - | Imipenem: ≤ 1 - 2 -≥4 (S, I, R) | Intermediate | 2 | 4-4 | |
| Gram - | Ceftazidime: ≤ 4 - 8 -≥16 (S, I, R) | Susceptible | < 1 | 4-4 | |
| Gram - | Imipenem: ≤ 1 - 2 - ≥4 (S, I, R) | Intermediate | 2 | 4-4 | |
| Gram - | Ceftazidime: ≤ 4 - 8 - ≥16 (S, I, R) | Susceptible | < 1 | 4-4 | |
| Gram - | Imipenem: ≤ 1 - 2 - ≥4 (S, I, R) | Susceptible | < 1 | 1-1 | |
| Gram - | Ceftazidime: ≤ 4 - 8 - ≥16 (S, I, R) | Susceptible | < 1 | 4-4 | |
| Gram+ | Ampicillin: ≤ 8 - ≥16 (S, R) | Susceptible | 4 | 8-No fragments | |
| Gram+ | Penicillin: ≤ 8 - ≥16 (S, R) | Susceptible | 2 | 8-No fragments | |
| Gram+ | Vancomycin: ≤ 4 -8/16- ≥32 (S, I, R) | Resistant | > 32 | No nucleoids-No fragments | |
| Gram+ | Ampicillin: ≤ 8 - ≥16 (S, R) | Resistant | > 32 | No nucleoids-No fragments | |
| Gram+ | Penicillin: ≤ 8 - ≥16 (S, R) | Resistant | > 32 | No nucleoids-No fragments | |
| Gram+ | Vancomycin: ≤ 4 -8/16- ≥32 (S, I, R) | Susceptible | < 1 | 4-No fragments | |
| Gram+ | Ampicillin: ≤ 8 - ≥16 (S, R) | Susceptible | < 1 | 8-No fragments | |
| Gram+ | Ampicillin: ≤ 8 - ≥16 (S, R) | Intermediate | 12 | 16-No fragments | |
| Gram+ | Ampicillin: ≤ 8 - ≥16 (S, R) | Resistant | > 16 | No nucleoids-No fragments | |
| Gram+ | Penicillin: ≤ 8 - ≥16 (S, R) | Susceptible | 2 | 8-No fragments | |
| Gram+ | Penicillin: ≤ 8 - ≥16 (S, R) | Resistant | > 16 | No nucleoids-No fragments | |
| Gram+ | Vancomycin: ≤ 4 -8/16- ≥32 (S, I, R) | Susceptible | 2 | 4-No fragments | |
| Gram+ | Vancomycin: ≤ 4 -8/16- ≥32 (S, I, R) | Resistant | > 32 | No nucleoids-No fragments | |
| Gram+ | Vancomycin: ≤ 4 -8/16- ≥32 (S, I, R) | Resistant | > 32 | No nucleoids-No fragments | |
| Gram+ | Vancomycin: ≤2 - 4-8 - ≥16 (S, I, R) | Susceptible | < 1 | 2-No fragments | |
| Gram+ | Vancomycin: ≤2 - 4-8 - ≥16 (S, I, R) | Susceptible | < 1 | 2-No fragments | |
Figure 9Two strains of . Whereas the resistant strain does not show lysis after vancomycin doses, the sensitive strain is clearly affected. There is no evidence of background of extracellular DNA fragments.